ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Embargoed until August 17, 4:00 PM ET:

Endocrine Deficiency as a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors (JCO: Original Report)
Torunn Yock, et al.
Request this article

Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated with Usual Interstitial Pneumonia (JCO PO: Original Report)
Takashi Kohno, et al.
Request this article

Embargoed until August 16, 4:00 PM ET:

Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries (JCO: Original Report)
Adam Olszewski, et al.
Request this article

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma (JCO: Original Report)
Jane Churpek, et al.
Request this article

Documenting Goals of Care Among Patients With Advanced Cancer: Results of a Quality Improvement Initiative (JOP: Original Contribution)
Safiya Karim, et al.
Request this article

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (JCO PO: Special Article)
Heather Cheng, et al.
Request this article

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of pCR for Breast Cancer Patients Treated With Neratinib in the I-SPY 2 TRIAL (JCO PO: Original Report)
Emanuel Petricoin, et al.
Request this article

Personalized Clinical Decision Making Through Implementation of a Molecular Tumorboard – A German Single Center Experience (JCO PO: Original Report)
Nikolas von Bubnoff, et al.
Request this article

Embargoed until August 15, 4:00 PM ET:

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (JCO: Original Report)
Yelena Janjigian, et al.
Request this article

Patient- and Hospital-Level Factors Associated With Readmission for Malignant Pleural Effusion (JOP: Original Contribution)
Theresa Yang, et al.
Request this article

Root Cause Analysis of Oncology Adverse Events in the Veterans Health Administration (JOP: Original Contribution) 
Maya Aboumrad, et al.
Request this article

ASCO Resource-Stratified Guidelines: Methods and Opportunities (JGO: Special Article)
Sarah Temin, et al.
Request this article

Retrospective Validation and Clinical Implementation of Automated Contouring of Organs at Risk in the Head and Neck: A Step Toward Automated Radiation Treatment Planning for Low- and Middle-Income Countries (JGO: Original Report)
Beth Beadle, et al.
Request this article

Embargoed until August 14, 4:00 PM ET:

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial (JCO: Original Report)
Mothaffar Rimawi, et al.
Request this article

Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer (JCO: Original Report) 
Karen Hoffman, et al.
Request this article

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer (JCO: Original Report)
Ramaswamy Govindan, et al.
Request this article

Embargoed until August 10, 4:00 PM ET:

Avoidable Mortality: The Core of the Global Cancer Divide (JGO: Original Report)
Felicia Marie Knaul, et al.
Request this article

Embargoed until August 9, 4:00 PM ET:

Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report From the St Jude Lifetime Cohort Study (JCO: Original Report)
Tara Brinkman, et al.
Request this article

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group (JCO: Original Report)
Douglas Hawkins, et al.
Request this article

Embargo Information

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.